Today: 21 May 2026
Baidu stock today: BIDU jumps on Kunlunxin Hong Kong IPO plan as AI-chip frenzy builds
4 January 2026
2 mins read

Baidu stock today: BIDU jumps on Kunlunxin Hong Kong IPO plan as AI-chip frenzy builds

NEW YORK, January 4, 2026, 06:55 ET — Market closed.

Baidu, Inc. (BIDU) shares closed up 14.9% at $150.30 on Friday, January 2, after the company disclosed plans to spin off and seek a Hong Kong listing for its artificial intelligence chip arm, Kunlunxin. The stock gained $19.50 and hit $151.05 intraday, just shy of its 52-week high.

The announcement lands as Chinese investors crowd into domestic AI-hardware stories, with U.S. export rules tightening supply for some top-end Nvidia processors in China. Recent Hong Kong listings have drawn heavy demand as Beijing pushes semiconductor self-sufficiency.

Hong Kong’s fundraising backdrop has also improved. A total of 114 companies raised $37.22 billion on the exchange’s main board in 2025, London Stock Exchange Group data showed, and UBS banker John Lee Chen-kwok pointed to a pipeline of more than 300 would-be issuers.

Baidu said it confidentially submitted a listing application to the Hong Kong Stock Exchange and has not finalised the size or structure of any offering. It said the spin-off — a transaction that would list Kunlunxin separately from its parent — remains subject to regulatory approvals and may not proceed. Citi analyst Alicia Yap wrote, “While timing is a bit sooner, it is within our expectation.” Investing

Jefferies analyst Thomas Chong raised Baidu’s price target to $181 from $159 and kept a buy rating, arguing the move could help “unlock” value. He estimated Kunlunxin at $16 billion to $23 billion, implying $9 billion to $13 billion of value to Baidu based on its stake, according to the note. TipRanks

A confidential filing lets a company start the vetting process without immediately publishing detailed IPO documents. It can keep timing flexible if market conditions change.

For Baidu investors, the questions now shift to when the Hong Kong process becomes public and how Kunlunxin’s valuation holds up once investors can examine its financials. Traders will also watch how much chip demand comes from outside customers versus Baidu’s own data-centre needs.

Baidu still leans on online advertising for much of its revenue, even as it spends heavily on AI cloud services and autonomous-driving technology. A separate listing would give the chip business its own financing channel and make its performance easier to benchmark against semiconductor peers.

The size of Friday’s move leaves the shares exposed to broader swings in risk appetite, particularly for U.S.-listed Chinese names. The stock ended near the top of its session range, a sign momentum traders remain active heading into Monday.

Before the next session, investors will look for any follow-up disclosure on timing and regulatory milestones for Kunlunxin. Analysts’ target changes and positioning in China ADRs could set the tone at Monday’s open.

Baidu’s next scheduled catalyst is earnings. Nasdaq’s earnings calendar currently estimates the company will report around February 17, putting a near-term focus on AI cloud demand, advertising trends and capital spending linked to chip development.

Macro data could also steer the tape this week. The Bureau of Labor Statistics has the December employment report scheduled for Friday, January 9 at 8:30 a.m. ET, with ISM surveys and other labour-market readings due earlier in the week.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Previous Story

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Tesla stock today: TSLA slides after delivery miss as BYD takes EV crown ahead of Jan. 28 earnings
Next Story

Tesla stock today: TSLA slides after delivery miss as BYD takes EV crown ahead of Jan. 28 earnings

Go toTop